155 related articles for article (PubMed ID: 37207314)
1. Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
Yarur AJ; Abreu MT; Deepak P; Beniwal-Patel P; Papamichael K; Vaughn B; Bruss A; Sekhri S; Moosreiner A; Gu P; Kennedy W; Dubinsky M; Cheifetz A; Melmed GY
Am J Gastroenterol; 2023 Nov; 118(11):2005-2013. PubMed ID: 37207314
[TBL] [Abstract][Full Text] [Related]
2. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
3. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study.
Yarur AJ; Bruss A; Moosreiner A; Beniwal-Patel P; Nunez L; Berens B; Colombel JF; Targan SR; Fox C; Melmed GY; Abreu MT; Deepak P
Gastroenterology; 2023 Oct; 165(4):963-975.e5. PubMed ID: 37499955
[TBL] [Abstract][Full Text] [Related]
4. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy.
van Hoeve K; Seyed Tabib NS; Dreesen E; Tops S; Hoffman I; Gils A; Ferrante M; Vermeire S
J Pediatr; 2022 Jan; 240():150-157.e4. PubMed ID: 34481805
[TBL] [Abstract][Full Text] [Related]
5. High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study.
Wilson A; Choi B; Sey M; Ponich T; Beaton M; Kim RB
BMC Gastroenterol; 2021 Feb; 21(1):77. PubMed ID: 33602145
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
7. Visceral Adipose Tissue Volumetrics Inform Odds of Treatment Response and Risk of Subsequent Surgery in IBD Patients Starting Antitumor Necrosis Factor Therapy.
Gu P; Chhabra A; Chittajallu P; Chang C; Mendez D; Gilman A; Fudman DI; Xi Y; Feagins LA
Inflamm Bowel Dis; 2022 May; 28(5):657-666. PubMed ID: 34291800
[TBL] [Abstract][Full Text] [Related]
8. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
9. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
10. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
Taks M; Pijls PA; Derijks LJ; Ten Broeke R; Grouls RJ; Curvers J; Gilissen LP
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):169-173. PubMed ID: 27749780
[TBL] [Abstract][Full Text] [Related]
11. Optimized Infliximab Induction Predicts Better Long-Term Clinical and Biomarker Outcomes Compared to Standard Induction Dosing.
Lawrence S; Faytrouni F; Harris RE; Irvine M; Carrion E; Scott G; Clarke B; Garrick V; Curtis L; Gervais L; Tayler R; Riou M; Hansen R; Jacobson K; Russell RK
J Pediatr Gastroenterol Nutr; 2022 Nov; 75(5):601-607. PubMed ID: 36048178
[TBL] [Abstract][Full Text] [Related]
12. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
13. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab.
Pouillon L; Ferrante M; Van Assche G; Rutgeerts P; Noman M; Sabino J; Vande Casteele N; Gils A; Vermeire S
Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1276-1283.e1. PubMed ID: 29203225
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of infliximab trough levels in maintenance therapy for 5-year sustained clinical remission in patients with inflammatory bowel disease.
Jalali Y; Gojdicova A; Sturdik I; Toth J; Koller T; Huorka M; Jalali M; Payer J; Hlavaty T
Bratisl Lek Listy; 2023; 124(7):485-492. PubMed ID: 37218475
[TBL] [Abstract][Full Text] [Related]
16. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease.
Gil Candel M; Gascón Cánovas JJ; Urbieta Sanz E; Gómez Espín R; Nicolás de Prado I; Iniesta Navalón C
Rev Esp Enferm Dig; 2020 May; 112(5):360-366. PubMed ID: 32338010
[TBL] [Abstract][Full Text] [Related]
18. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
[TBL] [Abstract][Full Text] [Related]
19. Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases.
Liefferinckx C; Bottieau J; Toubeau JF; Thomas D; Rahier JF; Louis E; Baert F; Dewint P; Pouillon L; Lambrecht G; Vallée F; Vermeire S; Bossuyt P; Franchimont D
Inflamm Bowel Dis; 2022 Feb; 28(2):208-217. PubMed ID: 33783494
[TBL] [Abstract][Full Text] [Related]
20. A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases.
Kantasiripitak W; Wicha SG; Thomas D; Hoffman I; Ferrante M; Vermeire S; van Hoeve K; Dreesen E
J Crohns Colitis; 2023 Jun; 17(6):896-908. PubMed ID: 36661279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
